Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Inclusion Criteria: 1. Healthy males or non-pregnant females; 2. Capable of providing written, informed consent; and , 3. Have submental bulging that is evaluated by the Investigator as "Moderate" or "Large". Exclusion Criteria: 1. History of prior treatment to reduce submental bulging; 2. History of derm fillers, chemical peels, or laser or radio frequency procedures in the neck/chin area within 12 months of screening; 3. History of botulinum toxin in the neck/chin area within 6 months of screening; 4. Any skin conditions (including, but not limited to: skin infections, psoriasis, eczema, keloids, tattoos or hypertrophic or tethered scars) or history of trauma in the treatment area that may affect study procedures; 5. A score of 4 (Extreme Laxity) on the Skin Laxity Assessment Scale at Visit 1 (Screening); 6. Any known hypersensitivity to the study drug and/or any of the components; 7. Prior or current enrollment in any Lithera/Neothetics sponsored LIPO-102/LIPO-202 study; 8. Concurrently enrolled in another investigational drug or device study or used any experimental or investigational drug or device within 30 days of screening; 9. Female subject who is pregnant or lactating; 10. Any medical condition that in the opinion of the Investigator might complicate study procedures or assessments or jeopardize the subject's safety, including, but not limited to: 1. any bleeding or connective tissue disorders; 2. any clinically significant kidney or liver disease; 3. any untreated thyroid disease; 4. asthma, COPD, diabetes (Type I and II) or cardiovascular disease 5. history of major surgery within 30 days prior to randomization, or planned surgery during the study period; 11. Used drugs with anticoagulant activity (including aspirin) within 14 days prior to randomization, β adrenergic receptor agonists or blockers, strong CYP3A inhibitors, or nonpotassium sparing diuretics (e.g., loop or thiazide diuretics) within 28 days prior to randomization; 12. Used tricyclic antidepressants or monoamine oxidase inhibitor medications within 14 days prior to randomization; 13. Unlikely or unable to adhere to the study visit schedule or comply with protocol procedures.